Wanbury Ltd submits APIs for regulatory approvals

Wanbury Limited, a leading pharmaceutical company with a good legacy in domestic and global API markets and branded formulations announced the Wanbury expanded regulatory submission for launch of new Active Pharmaceuticals Ingredients (APis).

For Diphenhydramine HCl, company submitted DMF to Malaysia and Singapore. The Company proposed to explore new market opportunities for Paroxetine HCl in Korea and Latin America by submitting the DMFs. Company also received formal audit report from MFDS (Korea FDA) for its Patalganga facility stating zero observation for the inspection conducted in April 2026.

Shares of Wanbury Limited was last trading in BSE at Rs. 256.05 as compared to the previous close of Rs. 259.35. The total number of shares traded during the day was 9838 in over 301 trades.

The stock hit an intraday high of Rs. 260.10 and intraday low of 254.35. The net turnover during the day was Rs. 2527116.00.

Source : Equity Bulls

Keywords

Wanbury INE107F01022 Pharmaceuticals APIs RegulatoryApprovals